Anti-Mouse PD-1 (Clone RMP1-30)- Purified (CODEX® Ready)

Home/PhenoCycler®, PhenoCycler® Validated Antibodies, Primary Monoclonal Antibodies/Anti-Mouse PD-1 (Clone RMP1-30)- Purified (CODEX® Ready)

Pricing & Details

Product No.C3441
Clone
RMP1-30
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Programmed Death-1, CD279
Isotype
Rat
IgG2b κ
Applications
PhenoCycler®
Prod No.
Size
Price
Avail.
Qty
Add to cart
C3441-50μg
50 µg
$125.00
In stock
Max:
Min: 1
Step: 1
Contact Us For Academic mAb Advantage Pricing

Antibody and Reporter Details

Reactivity Species
Mouse
Host Species
Rat
Concentration
0.5 mg/ml
Immunogen
Mouse PD-1 transfected BHK cells
Formulation
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4.
Storage and Handling
This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Applications and Recommended Usage?
Quality Tested by Leinco
FC
IHC FF
CODEX® This PD-1 (Clone RMP1-30) antibody is formulated to simplify the antibody preparation needed when performing a CODEX® barcode conjugate. The suggested concentration is 1.0 mg/ml.
Other Applications Reported In Literature ?
FC
Country of Origin
USA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
RMP1-30 activity is directed against mouse PD-1 (CD279).
Antigen Distribution
PD-1 is expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells.
Background
PD-1, a member of the CD28/CTLA-4 subfamily of the Ig superfamily, is a transmembrane protein expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells1,2. PD-1 is also retained in the intracellular compartments of human and mouse regulatory T cells (Tregs) and is co-expressed with CD25 on activated CD4+ T cells3. When stimulated via the T cell receptor (TCR), Tregs translocate PD-1 to the cell surface3. PD-1 is absent on naïve T cells and is inducibly expressed on T cells by T cell antigen receptor (TCR). B7-H1 (PD-L1; CD274) and B7-DC (PD-L2; CD273) have been identified as PD-1 ligands1. PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating antigen-presenting cells (APCs)2.

PD-1 acts as a T cell inhibitory receptor and plays a critical role in peripheral tolerance induction and autoimmune disease prevention as well as important roles in the survival of dendritic cells, macrophage phagocytosis, and tumor cell glycolysis2. PD-1 prevents uncontrolled T cell activity, leading to attenuation of T cell proliferation, cytokine production, and cytolytic activities. Additionally, the PD-1 pathway, consisting of PD-1 on T cells and PD-L1 on APCs, is a major mechanism of tumor immune evasion, and, as such, PD-1 is a target of cancer immunotherapy2.

RMP1-30 does not block the binding of B7-H1 or B7-DC to PD-11.
NCBI Gene Bank ID
UniProt.org
uniprot

References & Citations

1. Matsumoto K, Inoue H, Nakano T, et al. J Immunol. 172(4):2530-2541. 2004.
2. Zhao Y, Harrison DL, Song Y, et al. Cell Rep. 24(2):379-390.e6. 2018.
3. Raimondi G, Shufesky WJ, Tokita D, et al. J Immunol. 176(5):2808-2816. 2006.
4. Ding ZC, Habtetsion T, Cao Y, et al. Sci Rep. 7(1):12168. 2017.
5. Chatterjee S, Daenthanasanmak A, Chakraborty P, et al. Cell Metab. 27(1):85-100.e8. 2018.
6. Snell LM, MacLeod BL, Law JC, et al. Immunity. 49(4):678-694.e5. 2018.
7. Bradley CP, Teng F, Felix KM, et al. Cell Host Microbe. 22(5):697-704.e4. 2017.
8. Uchil PD, Pi R, Haugh KA, et al. Cell Host Microbe. 25(1):87-100.e10. 2019.
9. Timilshina M, You Z, Lacher SM, et al. Cell Rep. 27(10):2948-2961.e7. 2019.
10. Chow MT, Ozga AJ, Servis RL, et al. Immunity. 50(6):1498-1512.e5. 2019.
11. St Clair JB, Detanico T, Aviszus K, et al. PLoS One.12(1):e0170556. 2017.
12. Liu QZ, Ma WT, Yang JB, et al. Front Immunol. 9:1090. 2018.
13. Vanderleyden I, Fra-Bido SC, Innocentin S, et al. Cell Rep. 30(3): 611–619.e4. 2020.
14. Bally AP, Tang Y, Lee JT, et al. J Immunol. 198(1):205–217. 2017.
15. Quatrini L, Wieduwild E, Escaliere B, et al. Nat Immunol. 19(9):954-962. 2018.
16. Shimizu K, Sugiura D, Okazaki IM, et al. Mol Cell. 77(5):937-950.e6. 2020.
17. Karnowski A, Chevrier S, Belz GT, et al. J Exp Med. 209(11):2049-2064. 2012.
18. Park HJ, Kusnadi A, Lee EJ, et al. Cell Immunol. 278(1-2):76-83. 2012.
19. Huang JR, Tsai YC, Chang YJ, et al. J Immunol. 192(4):1972-1981. 2014.
20. Park SJ, Namkoong H, Doh J, et al. J Leukoc Biol. 96(5):939. 2014.
21. Puleston DJ, Zhang H, Powell TJ, et al. Elife. 3:e03706. 2014.
22. Lu X, Ding ZC, Cao Y, et al. J Immunol. 194(4):2011-2021. 2015.
23. Bally AP, Lu P, Tang Y, et al. J Immunol. 194(9):4545-4554. 2015.
24. Zeng, W., Liu, Z., Zhang, S. et al. Sci Rep. 6:36560. 2016.
25. Zhuang Z, Lai X, Sun J, et al. J Exp Med. 218(4):e20202187. 2021.
26. Mitchell JE, Lund MM, Starmer J, et al. Cell Rep. 35(2):108966. 2021.
27. Christian LS, Wang L, Lim B, et al. Cell Rep. 35(6):109118. 2021.
PhenoCycler®

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok